Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects

NCT06673238 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06673238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06673238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2024
Completion date
June 25, 2026
Enrollment
95 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer